Raymond James Raises Hologic (NASDAQ:HOLX) Price Target to $95.00

Hologic (NASDAQ:HOLX - Get Free Report) had its price target hoisted by Raymond James from $93.00 to $95.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm currently has an "outperform" rating on the medical equipment provider's stock. Raymond James' price target points to a potential upside of 20.56% from the stock's previous close.

HOLX has been the subject of several other research reports. Evercore ISI upped their price target on shares of Hologic from $78.00 to $82.00 and gave the company an "in-line" rating in a research report on Tuesday, October 1st. Royal Bank of Canada upped their price target on shares of Hologic from $86.00 to $89.00 and gave the company a "sector perform" rating in a research report on Tuesday. Leerink Partners reduced their price target on shares of Hologic from $95.00 to $90.00 and set an "outperform" rating for the company in a research report on Tuesday, October 8th. JPMorgan Chase & Co. upped their price target on shares of Hologic from $92.00 to $94.00 and gave the company an "overweight" rating in a research report on Tuesday. Finally, StockNews.com downgraded Hologic from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 27th. Five research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $89.25.

Hologic Stock Down 5.9 %

Shares of HOLX traded down $4.92 during trading hours on Tuesday, hitting $78.80. The company had a trading volume of 3,428,381 shares, compared to its average volume of 1,591,221. The firm has a fifty day moving average price of $81.06 and a 200-day moving average price of $78.08. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99. The stock has a market capitalization of $18.30 billion, a price-to-earnings ratio of 26.80, a P/E/G ratio of 2.98 and a beta of 0.98. Hologic has a 52-week low of $66.93 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts' consensus estimates of $1.01. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The business had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same quarter in the previous year, the firm earned $0.89 EPS. Hologic's revenue was up 4.5% on a year-over-year basis. On average, equities research analysts forecast that Hologic will post 4.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Hologic

A number of institutional investors have recently added to or reduced their stakes in HOLX. Wolff Wiese Magana LLC acquired a new stake in Hologic in the third quarter worth about $25,000. Innealta Capital LLC acquired a new stake in Hologic in the second quarter worth about $25,000. iA Global Asset Management Inc. acquired a new stake in Hologic in the first quarter worth about $37,000. Sunbelt Securities Inc. acquired a new stake in Hologic in the second quarter worth about $37,000. Finally, Cromwell Holdings LLC boosted its holdings in Hologic by 330.2% in the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider's stock worth $44,000 after acquiring an additional 416 shares in the last quarter. Institutional investors own 94.73% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.